EyePoint Pharmaceuticals (EYPT) Tops Q2 EPS by 8c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($0.61), $0.08 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $79.11 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Monolithic Power Systems (MPWR) Reiterated at Buy by Stifel on Reaching $4B Target
• Casey's General Stores (CASY) PT Lowered to $810 at BMO Capital
• MasterCraft (MCFT) Tops Q4 EPS by 3c, Beats on Revenue; Offers Guidance